A Phase I, Open-Label, Multicentre Dose-Escalation Study to Investigate the Safety and Pharmacokinetics of AZD4785 in Patients With Advanced Solid Tumours Where KRAS May Be an Important Driver of Tumour Survival

Trial Profile

A Phase I, Open-Label, Multicentre Dose-Escalation Study to Investigate the Safety and Pharmacokinetics of AZD4785 in Patients With Advanced Solid Tumours Where KRAS May Be an Important Driver of Tumour Survival

Recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Aug 2017

At a glance

  • Drugs AZD-4785 (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; First in man
  • Sponsors AstraZeneca
  • Most Recent Events

    • 26 Jul 2017 Planned number of patients changed from 60 to 50.
    • 16 Jun 2017 Planned End Date changed from 29 Aug 2019 to 30 Aug 2019.
    • 16 Jun 2017 Planned primary completion date changed from 29 Aug 2019 to 30 Aug 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top